Entos Pharmaceuticals

Weekly Recap of the Hottest M&A and Partnerships in the Biotech World! 🔥🤝 Merger and acquisition: 🔀                                                                                🇬🇧 Epsilogen Ltd acquires 🇺🇸 TigaTx | undisclosed financial terms | Lead asset: anti-EGFR IgA antibody for cancer  🇺🇸 Concentra Biosciences acquires 🇺🇸 Allakos Inc | Concentra will acquire Allakos for $0.33 in cash per share of Allakos common stock   Partnering: 🤝 🇫🇷 Sanofi collaborates with 🇺🇸 Nurix Therapeutics for Nurix’s undisclosed autoimmune degrader | Nurix to receive $15 million license extension fee and is eligible to receive up to $465 million in milestone payments   🇺🇸 Eli Lilly and Company partners with 🇺🇸 Sangamo Therapeutics, Inc. for Sangamo’s neurotropic AAV capsid | Sangamo to receive $18 million upfront and is eligible to receive up to $1.4 billion in milestone payments  🇬🇧 GSK partners with 🇰🇷 ABL Bio Inc. for ABL Bio's blood-brain barrier shuttle platform | ABL Bio to receive up to £77.1 million in upfront and near-term payments and is eligible to receive up to £2.075 billion in milestone payments   🇨🇦 Entos Pharmaceuticals partners with 🇳🇴 Circio Holding ASA for in vivo PLV-circVec delivery | undisclosed financial terms  Subscribe to our newsletter for more partnering updates!  🔗 https://lnkd.in/dsgz62YY #deals #partnering #mergers #acquisitions #biotech

Exciting news! ICYMI: Entos Pharmaceuticals and Circio Holding ASA are collaborating to combine Circio's durable circVec DNA vectors with our Fusogenix PLV delivery technology - a potential game-changer for genetic medicine, chronic disease treatments, and vaccines. This partnership opens up incredible possibilities for developing novel, potent, and *repeat-dosable* therapeutics! Check out Feliza Mirasol's article in BioPharm International for the full story: https://lnkd.in/gxVXsCdC  #biotech #pharma #genetherapy #innovation #collaboration #drugdelivery #medicaltechnology #lifesciences #DNAexpressionvectors #Fusogenix #PLV #advancedmedicines #geneticmedicines #biotech #deliverytechnology John Lewis Jason Ding, FCPA, FCA Arun Raturi Steve C. Erik Digman Wiklund Lubor Gaal

Are you attending ISPE Canada Affiliate on May 5-6 in Mississauga, Ontario? Be sure to go to our VP of Manufacturing Swapnil Ballal's talk: Risk as a Tool, Not a Hurdle: Driving Better Decisions in Pharma Operations. Connect with Swapnil Ballal to learn more! #ispecanada #eps2025 #pharmainnovation #biotech #Fusogenix #biomanufacturing

Our CEO, John Lewis, and CSO Arun Raturi will be at the 4th LNP Formulation & Process Development Summit in Boston from April 14-16! John Lewis will participate in a keynote panel discussion on April 16th at 8:30 am, focusing on strategic partnerships in the LNP industry, and will give an invited presentation at 2:45 pm on engineering the Fusogenix PLV platform for non-liver targeted RNA and DNA delivery. Connect with our Entos Pharmaceuticals team at the conference to discuss nucleic acid cargo delivery using Fusogenix PLV technology further. The full event guide is available here: https://lnkd.in/g33HQKsA #Fusogenix #PLV #advancedmedicines #LNPDevelopment

Circio Holding ASA and Entos Pharmaceuticals U.K. Ltd. have announced the initiation of a #research collaboration. Thomas Hansen Jason Ding, FCPA, FCA #healthcare #PharmaIndustrialIndia

Circio Holding ASA , a biotechnology company developing circular RNA technology for next-generation nucleic acid medicine, and Entos Pharmaceuticals, a clinical-stage genetic medicines company, have initiated a research collaboration that will involve joint development and in vivo delivery testing of Circio’s optimized circular RNA expression vectors (circVec) using the Entos proprietary Fusogenix PLV nucleic acid delivery technology. “Entos has demonstrated efficient and safe delivery of synthetic non-viral DNA vectors, both in mouse models, primates and clinical trials,” said Dr. Thomas Hansen, CTO of Circio. “The unique PLV chemistry enables direct fusion with the cell membrane and bypasses the endosomal uptake pathway. This feature has been shown to enhance delivery efficiency and reduce toxicity of DNA vectors. It is therefore a logical step for Circio to enter this research collaboration with Entos to explore the potential synergy of combining our complementary expression and delivery technologies. If successful, this partnership will aim to provide a joint platform for generating future therapeutic candidates in several disease areas of high unmet medical need.” “Entos is currently partnering with a number of key international genetic medicine companies for the expansion of the use of our Fusogenix PLV drug delivery system to enable the delivery of nucleic acid to target cells through direct fusion,” said Jason Ding, FCPA, FCA, CBO of Entos Pharmaceuticals. “We have selected to partner with Circio given their unique and impressive approach to circular RNA vector expression technologies for next generation nucleic acid medicine. This collaboration will seek to use Fusogenix PLV to enhance Circio’s circVec DNA vector delivery efficiency and reduce toxicity compared to LNP-formulations. This could have a considerable impact in novel applications in genetic medicine, chronic disease and vaccines.” Congratulations to all involved! Read the full article here: https://lnkd.in/eC_zgT8c

We're excited to share a new collaboration between Entos Pharmaceuticals and Circio Holding ASA to combine Circio's durable circVec DNA vectors with our Fusogenix PLV delivery technology. The combined technologies can allow future joint development of novel, potent, repeat-dosable therapeutic candidates and in vivo delivery testing for genetic medicine, chronic disease, and vaccines. Read the full press release here https://lnkd.in/gdYqdhxC #DNAexpressionvectors #Fusogenix #PLV #advancedmedicines #geneticmedicines #biotech #deliverytechnology John Lewis Jason Ding, FCPA, FCA Arun Raturi Steve C. Erik Digman Wiklund Lubor Gaal

March 26, The Pulse New Entos Pharmaceuticals hub to help retain biotech talent. By Stephanie Swensrude The head of Entos Pharmaceuticals (CEO John Lewis ) said a new hub that will enable research and development and biomanufacturing will help keep biotechnology talent in the Edmonton region. #biotechnology #biomanufacturing https://lnkd.in/g8gj3EUN.

Day 3 of the ACS Spring 2025 conference! DM Entos Pharmaceuticals Research Scientist Dr. Ritu Raturi to meet and chat about our PLV platform for advanced medicines. #drugdevelopment #PLV #Fusogenix #ACSSPRING2025 #drugdelivery Jitendra Kumar Arun Raturi